TCR2 Therapeutics Inc.
CIK 0001750019
Revenue (TTM)
—
Q1 May 2023
Net Income (TTM)
−$131.72M
−52.1% YoY
Q1 May 2023
EPS Diluted (TTM)
−$3.40
−49.4% YoY
Q1 May 2023
Gross Margin
—
Q1 May 2023
Operating Margin
—
Q1 May 2023
Net Margin
—
Q1 May 2023
Free Cash Flow (TTM)
−$115.55M
Q1 May 2023
Cash
$14.45M
Q1 May 2023
Total Debt
—
Q1 May 2023
Shares Outstanding
39.26M sh
Q1 May 2023
Revenue & Net Income
EPS (Diluted)
Cash Flow
Revenue Growth (YoY)
No data available for this metric.